Autologous Bone Marrow Therapy to Operative Site Following Modified Radical Mastectomy to Prevent Flap Complications

Breast cancer is the second leading cause of cancer-related deaths, second to lung cancer, with approximately 40,000 deaths caused by breast cancer annually. Breast cancer is also a global health problem, with more than one million cases of breast cancer diagnosed worldwide each year [1]. Though breast-conserving surgery is more and more welcomed among female patients, modified radical mastectomy (MRM) still plays an important role in the operation for breast cancer. Postoperative complications such as wound pain, hematoma, marginal necrosis, flap necrosis, seroma, wound infection, shoulder stiffness and prolonged drainage led to a delay of adjuvant therapy after the operation.